Advances in the systemic treatment of head and neck cancers

Current Opinion in Oncology

Volumn 22, Issue 3, 2010, Pages 200-205

  Specenier, Pol ^a   Vermorken, Jan B ^a  

^a ANTWERP UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Chemotherapy; Head and neck cancer; Metastatic; Recurrent; Targeted therapies

Indexed keywords

CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; FLUOROURACIL; GEFITINIB; METHOTREXATE; PLATINUM DERIVATIVE; PROTEIN TYROSINE KINASE INHIBITOR;

CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; HEAD AND NECK CARCINOMA; HUMAN; METASTASIS; OVERALL SURVIVAL; PRIORITY JOURNAL; RECURRENT CANCER; REVIEW; SQUAMOUS CELL CARCINOMA;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HEAD AND NECK NEOPLASMS; HUMANS; NEOPLASM RECURRENCE, LOCAL;

EID: 77951457576     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/CCO.0b013e3283376e15     Document Type: Review

References (38)

1. Specenier P, Vermorken JB. Current concepts for the management of head and neck cancer: chemotherapy. Oral Oncol 2009; 45:409-415.
2. Specenier P, Vermorken JB. Recurrent head and neck cancer: current treatment and future prospects. Expert Rev Anticancer Ther 2008; 8:375-391.
3. Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008; 359:1116-1127.
4. Licitra L, Rolland F, Bokemeyer C, et al. Biomarker potential of EGFR gene copy number by FISH in the phase III EXTREME study: platinum-based CT plus cetuximab in first-line R/M SCCHN. J Clin Oncol 2009; 27:15s. (suppl; abstr 6005).
5. Vermorken JB, Stohlmacher J, Davidenko I, et al. An analysis of safety in patients (pts) with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) receiving chemotherapy (CT) with or without panitumumab (pmab) in a phase III clinical trial (SPECTRUM). J Clin Oncol 2009; 27:15s. (suppl; abstr 6050).
6. Cho BC, Keum KC, Shin SJ, et al. Weekly docetaxel in patients with platinum-refractory metastatic or recurrent squamous cell carcinoma of the head and neck. Cancer Chemother Pharmacol 2009; 65:27-32.
7. Grau JJ, Caballero M, Verger E, et al. Weekly paclitaxel for platin-resistant stage IV head and neck cancer patients. Acta Otolaryngol 2008; 31:1-6.
8. Knoedler MK, Gauler T, Matzdorff A, et al. Multicenter phase II study of cetuximab plusdocetaxel in 84 patients with recurrent or metastatic, platinum-pretreated SCCHN. J Clin Oncol 2009; 27:15s. (suppl; abstr 6048).
9. Burtness BA, Manola J, Axelrod R, et al. A randomized phase II study of ixabepilone (BMS-247550) given daily x 5 days every 3 weeks or weekly in patients with metastatic or recurrent squamous cell cancer of the head and neck: an Eastern Cooperative Oncology Group study. Ann Oncol 2008; 19:977-983.
10. Martinez-Trufero J, Isla D, Adansa JC, et al. Phase II study of capecitabine as palliative treatment for patients with squamous head and neck cancer with locoregional and/or metastatic relapse after previous platinum-based treatment: final results of Spanish Head and Neck Cancer Group. J Clin Oncol 2009; 27:15s. (suppl; abstr 6047).
11. Hough B, Posner M, Chung C, et al. A phase II study of single agent OSI-7904Lin patients with metastatic or recurrent squamous cell carcinoma of the head and neck (SCCHN). J Clin Oncol 2009; 27:15s. (suppl; abstr e17005).
12. ParkS, LeeS, Park J, etal. Phase II study of oral S-1 in pretreated patients with recurrent or metastatic head and neck cancer. J Clin Oncol 2008; 26:15s. (suppl; 692s: abstr 17007).
13. Jehn CF, BoulikasT, Kourvetaris A, etal. First safety and response results of a randomized phase III study with liposomal platin in the treatment of advanced squamous cell carcinoma of the head and neck (SCCHN). Anticancer Res 2008; 28:3961-3964.
14. Gilbert J, Cmelak A, Shyr Y, et al. Phase II trial of irinotecan plus cisplatin in patients with recurrent or metastatic squamous carcinoma of the head and neck. Cancer 2008; 113:186-192.
15. Argiris A, Buchanan A, Brockstein B, et al. Docetaxel and irinotecan in recurrent or metastatic head and neck cancer: a phase 2 trial of the Eastern Cooperative Oncology Group. Cancer 2009; 115:4504-4513.
16. Ferrari D, Fiore J, Codeca C, et al. A phase II study of carboplatin and paclitaxel for recurrent or metastatic head and neck cancer. Anticancer Drugs 2009; 20:185-190.
17. Chang PM, Teng HW, Chen PM, et al. Methotrexate and leucovorin double-modulated 5-fluorouracil combined with cisplatin (MPFL) in metastatic/recurrent head and neck cancer. J Chin Med Assoc 2008; 71:336-341.
18. Hanai N, Terada A, Ozawa T, et al. A phase II study of docetaxel and cisplatin in patients with recurrent or unresectable squamous cell carcinoma of the head and neck. Gan To Kagaku Ryoho 2009; 36:1281-1285.
19. Wang TF, Chu SC, Kao RH, et al. A phase II study of weekly paclitaxel and epirubicin in recurrent or refractory squamous cell carcinoma of the head and neck. Jpn J Clin Oncol 2008; 38:459-463.
20. Mehra R, Sherman E, Ruth K, et al. Phase II study of pemetrexed (P) and gemcitabine (G) in patients with advanced head and neck cancer. J Clin Oncol 2009; 27:15s. (suppl; abstr 6052).
21. SpecenierPM,CiuleanuT, LatzJE, etal. Pharmacokinetic evaluation of platinum derived from cisplatin administered alone and with pemetrexed in head and neck cancer patients. Cancer Chemother Pharmacol 2009; 64:233-241.
22. Airoldi M, Cattel L, Milla P, et al. Paclitaxel and pegylated liposomal doxorubicin in recurrent head and neck cancer: clinical and unexpected pharmacokinetic interactions. Anticancer Res 2008; 28:2519-2527.
23. Zhang J, Lee JS, UrbaS, etal. A phase II trial evaluating weekly docetaxel and capacitabine in patients with metastatic or advanced, locally, recurrent head and neck cancer. J Clin Oncol 2009; 27:15s. (suppl; 313s: abstr 6051).
24. Machiels JM, Henry S, Zanetta S, et al. Phase II study of sunitinib in patients with recurrent and/or metastatic squamous head and neck carcinoma: The GORTEC 2006-01 study. J Clin Oncol 2009; 27:15s. (suppl; abstr 6024).
25. Choong NW, Kozloff M, Taber D, et al. Phase II study of sunitinib malate in head and neck squamous cell carcinoma. Invest New Drugs 2009 [Epub ahead of print].
26. Fountzilas G, Fragkoulidi A, Kalogera-Fountzila A, et al. A phase II study of sunitinib in patients with recurrent and/or metastatic nonnasopharyngeal head and neck cancer. Cancer Chemother Pharmacol 2010; 65:649-660.
27. Stewart JS, Cohen EE, Licitra L, et al. Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 2009; 27:1864-1871.
28. Cohen EE, Halpern AB, Kasza K, etal. Factors associated with clinical benefit from epidermal growth factor receptor inhibitors in recurrent and metastatic squamouscell carcinomaof the head and neck. Oral Oncol 2009; 45:155-160.
29. Argiris A, Ghebremichael M, Gilbert J, etal. A phase III randomized, placebocontrolled trial of docetaxel with or without gefitinib in recurrent or metastatic squamous cell carcinoma of the head and neck: a trial of the Eastern Cooperative Oncology Group (ECOG). J Clin Oncol 2009; 27:15s. (suppl; 303s: abstr 6011).
30. Nutting CM, van Herpen CM, Miah AB, etal. Phase II study of 3-APTriapine in patients with recurrent or metastatic head and neck squamous cell carcinoma. Ann Oncol 2009; 20:1275-1279.
31. Hanrahan EO, Kies MS, Glisson BS, et al. A phase II study of lona-farnib (SCH66336) in patients with chemorefractory, advanced squamous cell carcinoma of the head and neck. Am J Clin Oncol 2009; 32:274-279.
32. Brooks HD, Glisson B, Lu C, etal. Phase II study of dasatinib in the treatment of head and neck squamous cell carcinoma. J Clin Oncol 2009; 27:15s. (suppl; abstr 6022).
33. Tang PA, Siu LL, Chen EX, et al. Phase II study of ispinesib in recurrent or metastatic squamous cell carcinomaof the head and neck. Invest New Drugs 2008; 26:257-264.
34. Blumenschein GR Jr, Kies MS, Papadimitrakopoulou VA, etal. Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza, suberoylanilide hydro-xamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer. Invest New Drugs 2008; 26:81-87.
35. Gilbert J, Lee J, Argiris A, et al. Phase II randomized trial of bortezomib plus irinotecan or bortezomib with addition of irinotecan at progression in recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) (E1304): a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2009; 27:15s. (suppl; abstr 6020).
36. Cohen EE, Davis DW, Karrison TG, et al. Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study. Lancet Oncol 2009; 10:247-257.
37. Recchia F, Candeloro G, Di Staso M, et al. Maintenance immunotherapy in recurrent or metastatic squamous cell carcinoma of the head and neck. J Immunother 2008; 31:413-419.
38. Riechelmann H, Sauter A, Golze W, et al. Phase I trial with the CD44v6-targeting immunoconjugate bivatuzumab mertansine in head and neck squamous cell carcinoma. Oral Oncol 2008; 44:823-829.